Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 158

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 7
Chunk 158
---
 the year ended December 31, 2024, the Company made payments for research and development expenditures to Angiogenesis Foundation for which a Director of the Company is the CEO of the Foundation of $50 (2023 - $201 and 2022 - $105). Other than employment agreements and indemnification agreements with our management as described under “Item 10. – Additional Information,” there are no further related party transactions.
 

C.   Interests of experts and counsel
-------------------------------------
 
Not required.